R John Looney

Summary

Publications

  1. ncbi request reprint Periprosthetic osteolysis: an immunologist's update
    R John Looney
    Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, NY 1442, USA
    Curr Opin Rheumatol 18:80-7. 2006
  2. ncbi request reprint Autoimmunity and bone
    Edward M Schwarz
    Department of Orthopaedics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 665, Rochester, NY 14642, USA
    Ann N Y Acad Sci 1068:275-83. 2006
  3. ncbi request reprint B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Arthritis Rheum 50:2580-9. 2004
  4. pmc Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
  5. pmc Novel human transitional B cell populations revealed by B cell depletion therapy
    Arumugam Palanichamy
    Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Immunol 182:5982-93. 2009
  6. ncbi request reprint Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
    Jennifer H Anolik
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 56:3044-56. 2007
  7. ncbi request reprint Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo
    Edward M Schwarz
    The Center for Musculoskeletal Research, Box 665, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Orthop Res 21:1049-55. 2003
  8. ncbi request reprint Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
    Jennifer H Anolik
    University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Rheum 50:3580-90. 2004
  9. ncbi request reprint B cell depletion therapy in autoimmune diseases
    Inaki Sanz
    Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Front Biosci 12:2546-67. 2007
  10. pmc Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets
    Jennifer H Anolik
    Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, NY 14642, USA
    Immunol Res 45:144-58. 2009

Detail Information

Publications33

  1. ncbi request reprint Periprosthetic osteolysis: an immunologist's update
    R John Looney
    Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, NY 1442, USA
    Curr Opin Rheumatol 18:80-7. 2006
    ..Unfortunately, similar advances in the medical treatment of periprosthetic osteolysis have not occurred. This review will update the state of periprosthetic osteolysis...
  2. ncbi request reprint Autoimmunity and bone
    Edward M Schwarz
    Department of Orthopaedics, University of Rochester Medical Center, 601 Elmwood Avenue, Box 665, Rochester, NY 14642, USA
    Ann N Y Acad Sci 1068:275-83. 2006
    ..Thus, systemic factors produced by autoimmunity have a dramatic impact on active myelopoiesis and bone homeostasis...
  3. ncbi request reprint B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Arthritis Rheum 50:2580-9. 2004
    ..B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE...
  4. pmc Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
    James J Kobie
    Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Arthritis Res Ther 13:R209. 2011
    ..Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy...
  5. pmc Novel human transitional B cell populations revealed by B cell depletion therapy
    Arumugam Palanichamy
    Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Immunol 182:5982-93. 2009
    ..The characterization of multiple transitional B cell subpopulations provides important insights into human B cell development...
  6. ncbi request reprint Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
    Jennifer H Anolik
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 56:3044-56. 2007
    ..This study was undertaken to determine the magnitude, duration, and cause of these defects in rituximab-treated systemic lupus erythematosus (SLE) patients...
  7. ncbi request reprint Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo
    Edward M Schwarz
    The Center for Musculoskeletal Research, Box 665, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Orthop Res 21:1049-55. 2003
    ..Using the data from this pilot we provide a model power calculation for such a trial...
  8. ncbi request reprint Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
    Jennifer H Anolik
    University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arthritis Rheum 50:3580-90. 2004
    ....
  9. ncbi request reprint B cell depletion therapy in autoimmune diseases
    Inaki Sanz
    Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Front Biosci 12:2546-67. 2007
    ..Finally, we will discuss some of the many challenges and opportunities that the medical and scientific community should address in the foreseeable future...
  10. pmc Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets
    Jennifer H Anolik
    Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, NY 14642, USA
    Immunol Res 45:144-58. 2009
    ....
  11. ncbi request reprint Treatment of SLE with anti-CD20 monoclonal antibody
    R John Looney
    Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Curr Dir Autoimmun 8:193-205. 2005
    ..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab)...
  12. pmc A perspective on B-cell-targeting therapy for SLE
    R John Looney
    Division of Allergy Immunology Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Room G 6427C, Rochester, NY, 14642, USA
    Mod Rheumatol 20:1-10. 2010
    ....
  13. ncbi request reprint B cells as therapeutic targets for rheumatic diseases
    R John Looney
    Department of Medicine, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Curr Opin Rheumatol 16:180-5. 2004
    ....
  14. ncbi request reprint New therapies for systemic lupus erythematosus: cellular targets
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14420, USA
    Rheum Dis Clin North Am 32:201-15, xi. 2006
    ..This article discusses the B-cell abnormalities found in systemic lupus erythematosus and the clinical and immunologic effects of anti-B-cell therapies...
  15. doi request reprint The effects of rituximab on immunocompetency in patients with autoimmune disease
    R John Looney
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 58:5-14. 2008
  16. ncbi request reprint Vaccine responses in patients with rheumatoid arthritis
    Rajan Ravikumar
    University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Curr Rheumatol Rep 9:407-15. 2007
    ..Nevertheless, it is already clear that vaccination does induce response in many patients. Unfortunately, vaccination is underutilized in RA patients and needs to be aggressively promoted...
  17. ncbi request reprint B cell depletion therapy in systemic lupus erythematosus
    Jennifer Anolik
    Department of Medicine Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
    Curr Rheumatol Rep 5:350-6. 2003
    ..Recent open-label studies indicate that rituximab is safe and may be efficacious in the treatment of SLE, and continued study with randomized clinical trials is justified...
  18. ncbi request reprint New and promising treatments for rheumatoid arthritis
    R John Looney
    Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA
    Am J Orthop (Belle Mead NJ) 36:18-23. 2007
  19. ncbi request reprint B cell-targeted therapy in diseases other than rheumatoid arthritis
    R John Looney
    Allergy Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol Suppl 73:25-8; discussion 29-30. 2005
    ..Based on these reports, further controlled studies are warranted to optimize RTX as monotherapy and to develop combination therapies in patients with refractory autoimmune diseases...
  20. ncbi request reprint Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice
    Ping Li
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Rheum 50:265-76. 2004
    ..To investigate the mechanisms whereby tumor necrosis factor alpha (TNFalpha) increases osteoclastogenesis in vivo...
  21. ncbi request reprint B cell-targeted therapy for rheumatoid arthritis: an update on the evidence
    R John Looney
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Drugs 66:625-39. 2006
    ..Thus, therapies specifically targeting B cells do appear to be effective in the treatment of RA, providing direct evidence that B cells are important in the pathogenesis of RA...
  22. ncbi request reprint Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases
    R John Looney
    Autoimmunity Centers of Excellence ACE Immunocompetency Committee, Rochester, USA
    Clin Immunol 123:235-43. 2007
    ..Banking genetic material to allow genotyping should be considered particularly if a central repository for samples from different trials can be established...
  23. doi request reprint B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data
    R John Looney
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Drugs 70:529-40. 2010
    ..Thus, recent clinical trial data show that B cell-targeting therapies are beginning to fulfil their promise as treatments for SLE and there are good reasons to hope for further progress in the near future...
  24. doi request reprint Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
    H Travis Ichikawa
    University of Rochester Medical Center, Rochester, New York, USA
    Arthritis Rheum 64:493-503. 2012
    ..To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are critical in disease pathogenesis...
  25. ncbi request reprint The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    Jennifer H Anolik
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Arthritis Rheum 48:455-9. 2003
    ....
  26. doi request reprint Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
    ....
  27. pmc Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear
    R John Looney
    Department of Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Res 4:59-63. 2002
    ....
  28. doi request reprint Hydroxychloroquine-induced myopathy
    Jun Beom Kwon
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Rheumatol 16:28-31. 2010
    ..Moreover, this medication is often prescribed to treat illnesses whose clinical manifestations may include myopathy...
  29. doi request reprint Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin
    Andreea Coca
    University of Rochester, Department of Medicine, Allergy Immunology Rheumatology Division, Room G 6427C, 601 Elmwood Avenue, Rochester, New York 14642, USA
    Clin Immunol 132:10-8. 2009
    ..Both patients failed initial therapy with steroids and cyclosporine, either due to toxicity or lack of efficacy. Both patients responded dramatically to rabbit anti-thymocyte globulin (ATG)...
  30. ncbi request reprint A successful challenge in a patient with vancomycin-induced linear IgA dermatosis
    Sunil Joshi
    Department of Allergy Immunology Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Ann Allergy Asthma Immunol 93:101-3. 2004
    ..In each case, complete clearance of the skin lesions occurred with discontinued use of the drug. A subsequent rechallenge reproduced the eruption within hours to days...
  31. pmc Human basophils express amphiregulin in response to T cell-derived IL-3
    Yilin Qi
    David H Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Allergy Clin Immunol 126:1260-6.e4. 2010
    ..Amphiregulin produced by mouse hematopoietic cells contributes to the elimination of a nematode infection by a type 2 effector response...
  32. ncbi request reprint The therapeutic potential of anti-CD20 "what do B-cells do?"
    Robert Eisenberg
    Division of Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA med upenn edu
    Clin Immunol 117:207-13. 2005
    ..The increased use of rituximab, other anti-CD20 agents, and other B-cell targeting therapies holds great promise for substantial clinical benefits, as well as providing special opportunities to understand better disease pathogenesis...
  33. ncbi request reprint Will targeting B cells be the answer for Sjögren's syndrome?
    R John Looney
    Arthritis Rheum 56:1371-7. 2007